Sun Pharma (SUNPHARMA) Stock Price, Fundamentals & Analysis

What SUNPHARMA does

Sun Pharma (SUNPHARMA) is a stock listed on the National Stock Exchange of India in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry. Headquartered in Mumbai, India, the company develops, manufactures, and markets branded and generic formulations, as well as active pharmaceutical ingredients (APIs). Its product range spans therapeutic areas such as neuropsychiatry, cardiology, diabetes, oncology, and ophthalmology, and includes tablets, capsules, injectables, inhalers, and over-the-counter products. With approximately 47,000 employees, Sun Pharma operates in India, the United States, and internationally.

Key numbers explained

• The current price is 1,852.2 INR, up +0.12% today.
• The trailing P/E ratio of 36.8 shows how much investors pay per rupee of the company's last 12 months' earnings; a higher number can reflect growth expectations.
• The forward P/E ratio of 28.7 uses expected future earnings, which may indicate how the market views the company's growth outlook.
• The dividend yield of 0.86% represents the annual dividend payment as a percentage of the current share price.
• The ex-dividend date is Jul 7, 2026; buyers on or after this date are not eligible for the upcoming dividend.
• The company pays out 32% of its earnings as dividends, with the remainder typically retained for growth or debt reduction.
• The beta of 0.12 suggests the stock has historically been much less volatile than the overall market.
• The 52-week price range of 1,580 – 2,046.9 INR shows the lowest and highest traded prices over the past year.

What to watch

Investors often monitor Sun Pharma alongside peers such as Cipla (CIPLA) and Dr. Reddy's Laboratories (DRREDDY), which are also major players in the Indian pharmaceutical space. Factors that can affect this kind of stock include regulatory approvals in key markets like the United States, pricing pressure from generic competition, and currency fluctuations that impact international revenue. The company's debt-to-equity ratio of 5.5% is a measure of financial leverage that investors may track when assessing balance sheet strength. Earnings reports, scheduled for Nov 5, 2026, can drive short-term price movements and provide updates on revenue growth and margins.